MX354990B - Composicion de gotas para los ojos. - Google Patents

Composicion de gotas para los ojos.

Info

Publication number
MX354990B
MX354990B MX2014008442A MX2014008442A MX354990B MX 354990 B MX354990 B MX 354990B MX 2014008442 A MX2014008442 A MX 2014008442A MX 2014008442 A MX2014008442 A MX 2014008442A MX 354990 B MX354990 B MX 354990B
Authority
MX
Mexico
Prior art keywords
drop composition
eye drop
eye
composition
purin
Prior art date
Application number
MX2014008442A
Other languages
English (en)
Other versions
MX2014008442A (es
Inventor
Wera Stefaan
Auwerx Joeri
Goris Nesya
Blomsma Erwin
Debeurme Veerle
Neyts Johan
Roe Maryline
Puig Pascal
Billiet Ainola
Original Assignee
Aratana Therapeutics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aratana Therapeutics Nv filed Critical Aratana Therapeutics Nv
Publication of MX2014008442A publication Critical patent/MX2014008442A/es
Publication of MX354990B publication Critical patent/MX354990B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con una composición de gotas para los ojos que comprende 2-amino-9-[[(1S,2R)-1,2-bis (hidrometil)ciclopropil]metil] -1,9-dihidro-6H-purin-6-ona, y el uso de esta para el diagnóstico y tratamiento de infecciones oculares herpéticas en animales de compañía.
MX2014008442A 2012-01-20 2012-01-20 Composicion de gotas para los ojos. MX354990B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/050843 WO2013107515A1 (en) 2012-01-20 2012-01-20 Eye drop composition

Publications (2)

Publication Number Publication Date
MX2014008442A MX2014008442A (es) 2015-03-20
MX354990B true MX354990B (es) 2018-03-28

Family

ID=45592333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008442A MX354990B (es) 2012-01-20 2012-01-20 Composicion de gotas para los ojos.

Country Status (11)

Country Link
US (4) US9107943B2 (es)
EP (1) EP2804582B1 (es)
JP (1) JP5933033B2 (es)
CN (1) CN104144677B (es)
AU (3) AU2012366932B2 (es)
BR (1) BR112014017163A8 (es)
CA (1) CA2863500A1 (es)
ES (1) ES2575676T3 (es)
MX (1) MX354990B (es)
RU (1) RU2623066C2 (es)
WO (1) WO2013107515A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863500A1 (en) 2012-01-20 2013-07-25 Aratana Therapeutics Nv Eye drop composition
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
DK3119794T3 (en) 2014-06-25 2018-01-22 NuCana plc FORMULA CONTAINING A GEMCITABIN PRODRUG
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
CA3072768C (en) * 2017-08-27 2024-06-11 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
EP3989974A4 (en) * 2019-06-25 2023-07-19 Microbiotix, Inc. COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OCULAR INFECTIONS WITH FILOCICLOVIR

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE187173T1 (de) 1991-03-05 1999-12-15 Ajinomoto Kk Cyclopropanderivat
JPH0680670A (ja) 1992-09-03 1994-03-22 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
KR950011530A (ko) 1993-10-21 1995-05-15 도바 다다스 사이클로프로판 유도체 및 이를 함유하는 항바이러스제
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
JPH0841035A (ja) 1994-08-05 1996-02-13 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
JPH1129572A (ja) 1997-07-10 1999-02-02 Ajinomoto Co Inc 核酸誘導体の精製法
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
DK2153819T3 (da) * 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
JP2004026695A (ja) 2002-06-24 2004-01-29 M's Science Corp 水性点眼用製剤
CN101433721A (zh) * 2007-11-16 2009-05-20 华中科技大学 尼美舒利-羟丙基-β-环糊精包合物滴眼剂及其制备方法
WO2010042030A1 (en) 2008-10-07 2010-04-15 Medivir Ab Aspartyl protease inhibitors
RU2414898C1 (ru) * 2009-09-18 2011-03-27 Открытое Акционерное Общество "Валента Фармацевтика" Фармацевтическая композиция в форме раствора для инъекций, обладающая ноотропной активностью, и способ ее получения
AU2011380598B2 (en) 2011-11-10 2017-10-19 Aratana Therapeutics, Inc. Method for preparing cyclopropane derivatives
CA2863500A1 (en) 2012-01-20 2013-07-25 Aratana Therapeutics Nv Eye drop composition

Also Published As

Publication number Publication date
RU2623066C2 (ru) 2017-06-21
CA2863500A1 (en) 2013-07-25
JP2015505531A (ja) 2015-02-23
JP5933033B2 (ja) 2016-06-08
US10967074B2 (en) 2021-04-06
EP2804582B1 (en) 2016-03-30
CN104144677A (zh) 2014-11-12
WO2013107515A1 (en) 2013-07-25
US20150098904A1 (en) 2015-04-09
AU2012366932A1 (en) 2014-06-19
AU2017202421A1 (en) 2017-05-04
AU2012366932B2 (en) 2017-02-02
BR112014017163A8 (pt) 2017-07-04
US20210205478A1 (en) 2021-07-08
MX2014008442A (es) 2015-03-20
US9107943B2 (en) 2015-08-18
AU2019202510B2 (en) 2020-09-03
ES2575676T3 (es) 2016-06-30
US11904024B2 (en) 2024-02-20
BR112014017163A2 (pt) 2017-06-13
NZ625518A (en) 2016-02-26
CN104144677B (zh) 2016-11-23
US20240148909A1 (en) 2024-05-09
RU2014133697A (ru) 2016-03-20
EP2804582A1 (en) 2014-11-26
US20150352118A1 (en) 2015-12-10
AU2019202510A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
PH12015500925B1 (en) Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
EA201590215A1 (ru) Макроциклические пурины для лечения вирусных инфекций
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
MY171115A (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
MX2014008442A (es) Composicion de gotas para los ojos.
PH12014502577A1 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
WO2014097151A3 (en) Autotaxin inhibitors
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
UY35747A (es) Derivados sustituidos de fenilalanina
SG11201503231YA (en) METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
CL2014003123A1 (es) 5-amino [1,4], tiazinas como inhibidores de bace1; uso del compuesto contra la enfermedad de alzheimer.
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
UY35745A (es) Derivados sustituidos de fenilalanina
ES2543850R2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
TR201819263T4 (tr) Nörolojik hastalıkların tedavisi için pantotenat türevleri.
CL2015001681A1 (es) Unidad solida con alto contenido en fexofenadina; procedimiento de preparacion; y uso de la misma como antihistaminico, broncodilatador y/o para el tratamiento de alergias y/o urticarias.
WO2014193800A3 (en) Aptamers for the treatment of sickle cell disease
EP2968222A4 (en) METHOD, COMPOSITIONS AND DEVICES FOR TREATING MOTOR DISTURBANCES AND DEPRESSION SYMPTOMS RELATED TO MORBUS PARKINSON
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування

Legal Events

Date Code Title Description
FG Grant or registration